|
|
Press Releases
| All Releases |
|---|
 |
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
11-09-06
14.7 KB
|
| |
BALTIMORE, Nov 09, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced positive results from a 32 patient Phase II study using PROCHYMAL for the treatment of acute Graft vs. Host Disease or GVHD. In the study, 29 of 31, or 94% of evaluable patients responded after receiving two infusions of PROCHYMAL. More significantly, 23 pa...
|
|
Osiris Therapeutics Successfully Completes Private Placement with Friedli Corporate Finance
11-08-06
12.9 KB
|
| |
BALTIMORE, Nov 08, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), as previously announced on November 2, 2006, raised $20 million of newly issued convertible debt led by Friedli Corporate Finance, Inc. in Switzerland.
On October 30, 2006, Osiris issued $20 million in convertible promissory notes to several Swiss investors, pur...
|
|
Osiris Announces Third Quarter Results with Osteocel(R) Sales Growth of 50%
11-02-06
21.9 KB
|
| |
BALTIMORE, Nov 02, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced its financial results for the third quarter and nine months ended September 30, 2006.
Highlights
-- Osteocel sales increase by 50% or more for the 5th consecutive quarter
-- Osiris makes significant progress expanding its Phase 3 trial evalu...
|
|
Osiris Announces Third Quarter 2006 Financial Results Conference Call
10-31-06
9.2 KB
|
| |
BALTIMORE, Oct 31, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) will report its financial results for the third quarter ended September 30, 2006, after the close of trading on the NASDAQ Global Market on Thursday November 2, 2006. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Cary J. Claiborne, Chief Financia...
|
|
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) in Treatment-Resistant Crohn's Disease
10-19-06
14.4 KB
|
| |
BALTIMORE, Oct 19, 2006 (BUSINESS WIRE) -- Osiris Therapeutics (NASDAQ:OSIR) announced positive results from a pilot phase II study using PROCHYMAL for the treatment of patients with moderate to severe Crohn's disease who had failed to respond to standard treatments such as steroids and infliximab (Remicade(R)). In the study, every patient evaluate...
|
|
Osiris is Granted European Manufacturing Certification for PROCHYMAL(TM)
10-17-06
11.5 KB
|
| |
BALTIMORE, Oct 17, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) has received manufacturing authorization to distribute PROCHYMAL into Europe for its Phase III clinical trial. Distribution of product in Europe requires Good Manufacturing Practice certification, which was granted by a European auditor after a comprehensive review o...
|
|
Osiris Therapeutics Receives Approval from Health Canada to Conduct Phase III Clinical Trial for Lead Stem Cell Drug
10-11-06
11.1 KB
|
| |
BALTIMORE, Oct 11, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) has received regulatory approval to expand patient enrollment into Canada for its ongoing Phase III pivotal trial evaluating PROCHYMAL(TM) for the treatment of Graft vs. Host Disease.
Graft vs. Host Disease or GVHD is a life threatening immunological reaction tha...
|
|
Osiris Therapeutics to Present at BIO Investor Forum
10-10-06
8.3 KB
|
| |
BALTIMORE, Oct 10, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company, announced today that C. Randal Mills, Ph.D., President and CEO, will be presenting at the 2006 BIO Investor Forum in San Francisco, California on October 19, 2006. The presentation is scheduled for 1:20 PM, PST, 4:20 PM EST. ...
|
|
Osiris Therapeutics Named to Russell Index
09-18-06
9.0 KB
|
| |
BALTIMORE, Sep 18, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company, announced today that it will be added to the broad-market Russell 3000 Index. The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies based on total market capitalization.
Membership in the Rus...
|
|
Osiris Therapeutics to Present at UBS Global Life Sciences Conference
09-15-06
8.4 KB
|
| |
BALTIMORE, Sep 15, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, will be presenting at the UBS G...
|
|
|
 |
Stock Information
OSIR - (NASDAQ)
$6.57
+ 0.09
|
11-20-09
4:11 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
|
|
|
|
Shareholder Tools
|
|
